KP-1212

KP-1212 is a **novel nucleoside analog** developed as an experimental antiretroviral agent for **HIV-1 infection**. It is not a chain terminator like many traditional nucleoside reverse transcriptase inhibitors (NRTIs), but instead acts as a **viral mutagen**: when incorporated into viral DNA during replication, KP-1212 increases the mutation rate within the HIV-1 genome, particularly causing A-G and G-A transition mutations, with the goal of pushing the virus population over its "error catastrophe" limit, leading to loss of viral viability and collapse of the viral population. KP-1212 is designed to be selectively incorporated by viral polymerase but not significantly by human polymerases, thus showing a favorable safety profile and low genotoxicity. Its oral prodrug is known as KP-1461. In clinical studies (including Phase II), KP-1212 increased mutation rates in HIV but did not provoke a sustained reduction in viral load. KP-1212 has been shown to potentiate the effect of ribonucleotide reductase inhibitors in cell culture, leading to increased viral mutational load and enhanced antiviral activity when used in combination[1][2][3][4][5][6].

Other names

5,6-dihydro-5-aza-2'-deoxycytidine